LEXINGTON, Mass., Jan. 22, 2018 /PRNewswire/ — Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that it has received authorization of its Clinical Trial Application fro…